Friday, January 27, 2023
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for infectious disease clinicians, internists, intensivists, geriatricians, public health officials, and other clinicians who treat and manage patients with or at risk for Shewanella spp. bloodstream infections.
The goal of this activity is to describe the incidence of and risk factors for development of Shewanella spp. bloodstream infections, based on findings of a population-based surveillance study in Queensland, Australia, during 2000-2019.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 3/17/2022
Valid for credit through: 3/17/2023
processing....
Note: It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, product names related to microbial identification platforms are provided in this activity in an effort to clearly depict the research methodology. The use of manufacturer names should not be viewed as an endorsement of any specific product or manufacturer.
The epidemiology of bloodstream infections caused by Shewanella spp. is not well defined. Our objective was to define the incidence and determinants of Shewanella spp. bloodstream infections by using population-based surveillance in Queensland, Australia during 2000‒2019. The incidence was 1.0 cases/1 million persons annually and was highest during summer and in the tropical Torres and Cape region. Older persons and male patients were at highest risk. At least 1 concurrent condition was documented in 75% of case-patients, and 30-day all cause case-fatality rate was 15%. Aging populations in warm climates might expect an increasing burden of these infections.
Shewanella spp., most commonly S. algae and S. putrefaciens, are infrequent but occasionally severe causes of human infection associated with exposure to warm marine environments[1,2]. Cases of otogenic and skin and soft tissue infections caused by S. (Pseudomonas) putrefaciens were described in the 1960s, and case series of bacteremic infections were reported in subsequent decades[3,4]. Vignier et al. reported 16 cases of Shewanella spp. infection that occurred in Martinique during 1997–2012 and identified an additional 239 cases in review of the published literature during 1973–2011[5]. That study observed that otogenic, skin and soft tissue, abdominal/biliary tract, and respiratory tract foci of infection were most common, and that 71 (28%) cases were bacteremic[5]. Shewanella spp. are frequently coisolated with other organisms, most notably Enterobacterales and Aeromonas and Vibrio spp., and occasionally might develop major antimicrobial drug resistance[2,5,6].
As a result of their rarity, the epidemiology of Shewanella spp. bloodstream infections (BSIs) is poorly defined. The existing body of literature is limited to case reports and small series. In addition, as a result of developments in genomic and phenotypic testing, it has been recognized that before the current millennium many reports of S. putrefaciens infection might have been actually caused by S. algae[7]. The objective of this study was to determine the contemporary incidence of and risk factors for development of Shewanella spp. BSIs in the population of Queensland, Australia.
